Results 11 to 20 of about 91,427 (251)

Liposomal amphotericin B—the past [PDF]

Journal of Antimicrobial Chemotherapy, 2022
Abstract The discovery of amphotericin B, a polyene antifungal compound, in the 1950s, and the formulation of this compound in a liposomal drug delivery system, has resulted in decades of use in systemic fungal infections. The use of liposomal amphotericin B formulation is referenced in many international guidelines for the treatment of ...
R J Brüggemann, G M Jensen, C Lass-Flörl   +2 more
openaire   +3 more sources

In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against Candida auris

Pharmaceutics, 2021
Treatment of invasive infections caused by Candida auris is challenging due to the limited therapeutic options. The combination of antifungal drugs may be an interesting and feasible approach to be investigated.
Unai Caballero, Elena Eraso, Guillermo Quindós, Nerea Jauregizar   +3 more
doaj   +1 more source

Black and white teas as potential agents to combine with amphotericin B and protect red blood cells from amphotericin B-mediated toxicity

Brazilian Journal of Biology, 2018
Amphotericin B is a fungicidal substance that is treatment of choice for most systemic fungal infections affecting immunocompromised patients. However, severe side effects have limited the utility of this drug.
V. M. Oliveira, N. M. Khalil, E. Carraro
doaj   +1 more source

Do Ophthalmic Solutions of Amphotericin B Solubilised in 2-Hydroxypropyl-γ-Cyclodextrins Possess an Extended Physicochemical Stability?

Pharmaceutics, 2020
Fungal keratitis is a sight-threatening disease for which amphotericin B eye drops is one of the front-line treatments. Unfortunately, there are currently no commercial forms available, and there is little data concerning the long-term stability of ...
Philip Chennell, Mouloud Yessaad, Florence Abd El Kader, Mireille Jouannet, Mathieu Wasiak, Yassine Bouattour, Valérie Sautou   +6 more
doaj   +1 more source

Therapeutic potential of Calotropis gigantea extract against invasive pulmonary aspergillosis: In vitro and in vivo study

Asian Pacific Journal of Tropical Biomedicine, 2022
Objective: To characterize the antifungal activity of methanolic leaf extract of Calotropis gigantea alone or in combination with amphotericin B against invasive pulmonary aspergillosis in mice. Methods: GC/MS was used for analysis of active constituents
Enas M Ali, Manal A Alfwuaires, Gehan M Badr   +2 more
doaj   +1 more source

Amphotericin B-Induced Encephalopathy

Pediatric Neurology Briefs, 1995
Three children with refractory leukemia treated by bone marrow transplantation at the Children’s National Medical Center, Washington, DC, developed encephalopathy, leukoencephalopathy, and parkinsonism after receiving high-dose amphotericin B for ...
J Gordon Millichap
doaj   +1 more source

Efficacy of combination therapy of amphotericin and posaconazole in treatment of mucormycosis

Journal of Applied Pharmaceutical Research, 2023
Background: Mucormycosis is an opportunistic systemic fungal infection which is debilitating caused by order Mucorales. The standard management of mucormycosis consists of aggressive debridement of the infected tissue and parenteral anti-fungal therapy ...
Sridhara S, Ramesh Sanappa, Nandini P, Gayatri Jayan, Gangadhara KS   +4 more
doaj   +1 more source

Preventing or attenuating amphotericin B nephrotoxicity with dopamine receptor agonists: a literature review [PDF]

Trends in Pharmaceutical Sciences, 2015
Nephrotoxicity is generally considered as the most clinically significant and dose-limiting adverse reaction of amphotericin B. Currently, only the clinical effectiveness of salt loading and administering lipid formulations of amphotericin B have been ...
Iman Karimzadeh, Hossein Khalili, Mohammad Mahdi Sagheb   +2 more
doaj   +2 more sources

Using single-dose liposomal amphotericin B for cryptococcal meningitis induction therapy: nurse pearls and practical perspectives [version 1; peer review: 2 approved]

Wellcome Open Research
Background In Uganda where the burden of HIV-associated cryptococcal meningitis is high, conventional amphotericin B deoxycholate has been standard to manage patients with cryptococcal meningitis in research settings.
Richard Kwizera, Cynthia Ahimbisibwe, Jane Frances Ndyetukira, David B. Meya, Carol Namujju   +4 more
doaj   +1 more source

Case report: Reversible encephalopathy associated with liposomal amphotericin B in a patient with cryptococcal meningitis

Frontiers in Neurology, 2022
Liposomal amphotericin B (L-AMB) is an anti-fungus medicine that has fewer side effects than traditional amphotericin B (AMB). Neurotoxicity of L-AMB has rarely been observed, and only one case of leukoencephalopathy during intravenous L-AMB has been ...
Si Luo, Han Wen, Meihong Zhou, Chengsi Wu, Daojun Hong   +4 more
doaj   +1 more source